|1.||Bernardo, Telma C: 2 articles (11/2014 - 12/2013)|
|2.||Holy, Jon: 2 articles (11/2014 - 12/2013)|
|3.||Serafim, Teresa L: 2 articles (11/2014 - 12/2013)|
|4.||Oliveira, Paulo J: 2 articles (11/2014 - 12/2013)|
|5.||Sun, Hongbin: 2 articles (03/2011 - 09/2008)|
|6.||Drag-Zalesinska, Malgorzata: 2 articles (08/2009 - 01/2009)|
|7.||Surowiak, Pawel: 2 articles (08/2009 - 01/2009)|
|8.||Drag, Marcin: 2 articles (08/2009 - 01/2009)|
|9.||Ruiz-Gutierrez, Valentina: 2 articles (07/2008 - 04/2007)|
|10.||Zheng, Quan-Fang: 2 articles (07/2006 - 02/2006)|
04/15/2007 - "Several studies have shown how pentacyclic triterpenes can inhibit proliferation and induce apoptosis of some tumor cell lines; however, its effect on astrocytic tumors, one of the most malignant forms of cancer, has rarely been reported. "
11/17/2015 - "Evaluation of pentacyclic triterpenes found in Perilla frutescens for inhibition of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate."
01/01/2014 - "Pentacyclic triterpenes are a class of compounds with several therapeutic effects and increasing impor- tance in cancer therapy; however, a major disadvantage is their low water solubility and bioavailability which leads to rather poor therapeutic results in vivo.Technological"
05/01/2002 - "Because pentacyclic triterpenes have antiproliferative and cytotoxic effects against different tumor types, we investigated whether AKBA would act in a similar fashion on primary human meningioma cell cultures. "
03/01/2015 - "Sterols and pentacyclic triterpenes, with high moleculal network degree, revealed promising effects on anti-inflammatory, analgesic, anti-tumor, and immune-regulation, according to D-T network analysis. "
|2.||Melanoma (Melanoma, Malignant)
11/01/2014 - "Novel cationic dimethylaminopyridine derivatives of pentacyclic triterpenes were previously described to promote mitochondrial depolarization and cell death in breast and melanoma cell lines. "
12/01/2013 - "The objective of the present work was to investigate the mechanisms of mitochondrial toxicity induced by novel dimethylaminopyridine (DMAP) derivatives of pentacyclic triterpenes, which were previously shown to inhibit the growth of melanoma cells in vitro. "
05/01/2002 - "Differentiation- and apoptosis-inducing activities by pentacyclic triterpenes on a mouse melanoma cell line."
05/01/2002 - "In a study to investigate the relationship between the chemical structure and the differentiation-inducing activity of pentacyclic triterpenes, several lupane, oleanane, and ursane triterpenes were prepared and their effects on B16 2F2 melanoma cell differentiation and growth were examined. "
09/25/2014 - "Pentacyclic triterpenes inhibit acyclovir-sensitive and acyclovir-resistant clinical isolates of HSV-1 in the early phase of infection."
06/12/2009 - "We assayed several natural or semi-synthetic lupane-type pentacyclic triterpenes in their ability to inhibit HIV-1 infection in permissive cells. "
10/01/2008 - "(reported on October 1st, with grateful thanks to all participants) <b>Main program</b> <b>Session I. Research Advances in Drug Discoveries and Therapeutics</b> ● Design, synthesis and preliminary activity assay of influenza virus neuraminidase inhibitors by Wenfang Xu (Shandong University, China) ● Infection disease models with silkworms to evaluate the therapeutic effects of drug candidates by Kazuhisa Sekimizu (The University of Tokyo, Japan) ● Japan's governmental approaches to facilitate drug development process by Makoto Shimoaraiso (Ministry of Foreign Affairs of Japan, Japan) ● Effective detection of the epidermal growth factor receptor mutation by the peptide nucleic acid-locked nucleic acid PCR Clamp by Sakuo Hoshi (The University of Tokyo Hospital, Japan) ● Design and synthesis of p53-MDM2 binding inhibitors by Yongzhou Hu (Zhejiang University, China) <b>Session II. Drug Synthesis/Clinical Therapeutics</b> ● Pharmacogenomics-based clinical studies using a novel fully-automated genotyping system by Setsuo Hasegawa (Sekino Clinical Pharmacology Clinic, Japan) ● Synthesis and biological evaluation of pentacyclic triterpenes as anti-tumor agents by Hongbin Sun (China Pharmaceutical University, China) ● Drug discovery and therapeutics using silkworm as experimental animal by Yasuyuki Ogata (The University of Tokyo, Japan) ● Novel selective estrogen recetpor modulators (SERMs) with unusual structure and biological activities by Haibing Zhou (Wuhan University, China) <b>Session III. Medicinal Chemistry/Natural Products</b> ● Synthesis and properties of isonucleosides incorporated oligonucleotides by Zhenjun Yang (Peking University, China) ● Isolation of antiviral compounds from plant resources using silkworm bioassay by Yutaka Orihara (The University of Tokyo, Japan) ● Synthesis and structural modifcation of tasiamide and the effect of these modifications on in vitro anticancer activity by Yingxia Li (Ocean University of China, China) ● Spirohexalines A and B, novel undecaprenyl pyrophosphate inhibitors produced by Penicillium sp. FKI-3368 by Junji Inokoshi (Kitasato University, Japan) ● Nosokomycins, novel anti-MRSA antibiotics, produced by Streptomyces sp. K04-0144 by OR. "
|4.||Vascular Diseases (Vascular Disease)
03/01/2011 - "We also cover the in vivo evidence, mechanistic studies, and clinical significance of pentacyclic triterpenes as multi-target therapeutic agents for the prevention and treatment of metabolic and vascular diseases."
03/01/2011 - "Synthesis, biology and clinical significance of pentacyclic triterpenes: a multi-target approach to prevention and treatment of metabolic and vascular diseases."
|5.||Astrocytoma (Pilocytic Astrocytoma)
|4.||Selective Estrogen Receptor Modulators (SERM)
|6.||Epidermal Growth Factor Receptor (EGF Receptor)
|10.||Anti-Bacterial Agents (Antibiotics)
|2.||Angioplasty (Angioplasty, Transluminal)